
|Videos|September 9, 2022
Use of PARP Inhibitors in Breast Cancer: Implications for Pharmacy Practice
About 1 in 8 women in the United States will develop breast cancer in their lifetime. Overall mortality for breast cancer has decreased over the years with the addition of complex treatment, such as PARP inhibitors. The webcast discusses this class of medications and see how they fit into the treatment paradigm for breast cancer.
Advertisement
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Approves First Oral Targeted BTKi Treatment for Patients with Chronic Hives
2
Pfizer Agrees to Lower Certain Drug Prices in US, Aligning With ‘Most-Favored Nation’ Plan
3
Policy Update: Pfizer Pricing and Pediatric Cancer AI
4
UB-VV111: First In Vivo CAR T Candidate Moves Forward With FDA Fast Track Designation
5